In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols Babesia test for samples received on April 20, 2020 at the Charlotte, Dallas, Phoenix, St. Louis and Tampa laboratories. Be watching for details on an upcoming webinar that will provide you with an overview of implementing this testing.
Check out the Communication page for the complete details by clicking the link: Communications
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
We have now added a new section called the "Assay History List" to the "At A Gla...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...